Atossa Therapeutics (ATOS) Operating Leases (2019 - 2020)
Atossa Therapeutics (ATOS) posted quarterly Operating Leases of $1217.0 for Q3 2020, down 91.32% year-over-year from $14018.0 in Q4 2019, and down 74.22% quarter-over-quarter from $4720.0 in Q2 2020.
Atossa Therapeutics (ATOS) Operating Leases (2019 - 2020) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Operating Leases for 2 consecutive years, with $1217.0 the latest figure, recorded in Q3 2020.
- In Q3 2020, Operating Leases fell 91.32% year-over-year to $1217.0; the TTM figure through Sep 2020 stood at $1217.0 (down 91.32% YoY), while the FY2019 annual figure was $11108.0, changed N/A from the prior year.
- Operating Leases fell to $1217.0 in Q3 2020 per ATOS's latest filing, from $4720.0 in the prior quarter.
- Across five years, Operating Leases topped out at $37397.0 in Q1 2019 and bottomed at $1217.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Atossa Therapeutics | 22.79 Mn | 22.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 1,217.00 |
| Jun 30, 2020 | 4,720.00 |
| Mar 31, 2020 | 8,013.00 |
| Dec 31, 2019 | 11,108.00 |
| Sep 30, 2019 | 14,018.00 |
| Jun 30, 2019 | 24,027.00 |
| Mar 31, 2019 | 37,397.00 |